The syntheses of combretastatin A-4 from gallic acid and of three combretastatin-based hybrids are described. Starting from commercial gallic acid, the phosphonium salt (3,4,5-trimethoxybenzylphosphonium bromide) is synthesized and coupled, through a Wittig reaction, with several aldehydes, including methoxymethyl-protected isovanillin, the aldehyde γ-bicyclohomofarnesal having a labdane skeleton, 3-(3-pyridyl) propanal, and furfural. The biological properties of the cis-coupled compounds as cytotoxic, antiviral and antifungal agents are also reported. In addition, pyrogallol, gallic and 3,4,5-trimethoxybenzoic acids have been studied biologically.
PettitG.R., SinghS.B., HamelE., LinC.M., AlbertsD.S., Garcia-KendalD. (1989) Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor. Experientia, 45, 209–211.
2.
(a) BibbyM.C. (2002) Combretastatin anticancer drugs. Drugs Future, 27, 475–480;(b) Pinney KG, Jelinek C, Edvardsen K, Chaplin DJ, Pettit GR. (2005) The discovery and development of the combretastatins. In Anticancer Agents from Natural Products. Kingston D. Newman D. Cragg G. (Eds). CRC Press: Boca Raton, F, 23–46; (c). Theeramunkong S, Caldarelli A, Massarotti A, Aprile S, Caprioglio D, Zaninetti R, Teruggi A, Pirali T, Grosa G, Cesare Tron G, Genazzani AA. (2011) Regioselective Suzuki coupling of dihaloheteroaromatic compounds as a rapid strategy to synthesize potent rigid combretastatin analogues. Journal of Medicinal Chemistry, 54, 4977–4986.
3.
(a) WestC.M., PriceP. (2004) Combretastatin A4 phosphate. Anti-Cancer Drugs, 15, 179–187;(b) Siemann, DW, Chaplin DJ, Walicke PA. (2009) A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opinion on Investigational Drugs, 18, 189–197.
4.
DelmonteA., SessaC. (2009) AVE8062: a new combretastatin derivative vascular disrupting agent. Expert Opinion on Investigational Drugs, 18, 1541–1548.
5.
(a) NamN.H. (2003) Combretastatin A-4 analogues as antimitotic antitumor agents. Current Medicinal Chemistry, 10, 1697–1722;(b) Tron GC, Pirali T, Sorba G, Pagliai F, Busacca S, Genazzani AA. (2006) Medicinal chemistry of combretastatin A4: present and future directions. Journal of Medicinal Chemistry, 49, 3033–3044; (c) Shan Y, Zhang J, Liu Z, Wang M, Dong Y. (2011) Developments of combretastatin A-4 derivatives as anticancer agents. Current Medicinal Chemistry, 18, 523–538.
6.
(a) GaukrogerK., HadfieldJ.A., LawrenceN.J., NolanS., McGownA.T. (2003) Structural requirements for the interaction of combretastatins with tubulin: how important is the trimethoxy unit?Organic & Biomolecular Chemistry, 1, 3033–3037;(b) Beale TM, Myers RM, Shearman JW, Charnock-Jones DS, Brenton JD, Gergely FV, Ley SV. (2010) Antivascular and anticancer activity of dihalogenated A-ring analogues of combretastatin A-4. MedChemComm, 1, 202–208.
7.
JanikM.E., BaneS.L. (2002) Synthesis and antimicrotubule activity of combretatropone derivatives. Bioorganic & Medicinal Chemistry, 10, 1895–1903.
8.
(a) BanwellM.G., HamelE., HocklessD.C., Verdier-PinardP., WillisA.C., WongD.J. (2006) 4,5-Diaryl-1H-pyrrole-2-carboxylates as combretastatin A-4/lamellarin T hybrids: synthesis and evaluation as anti-mitotic and cytotoxic agents. Bioorganic & Medicinal Chemistry, 14, 4627–4638;(b) Shen L, Yang X, Yang B, He Q, Hu Y. (2010) Novel hybrids from lamellarin D and combretastatin A 4 as cytotoxic agents. European Journal of Medicinal Chemistry, 45, 11–18.
9.
QuintinJ., RoullierC., ThoretS., LewinG. (2006) Synthesis and anti-tubulin evaluation of chromone-based analogues of combretastatins. Tetrahedron, 62, 4038–4051.
GonzálezM.A., Correa-RoyeroJ., AgudeloL., MesaA., Betancur-GalvisL. (2009) Synthesis and biological evaluation of abietic acid derivatives. European Journal of Medicinal Chemistry, 44, 2468–2472.
12.
GonzálezM.A., Pérez-GuaitaD., Correa-RoyeroJ., ZapataB., AgudeloL., Mesa-ArangoA., Betancur-GalvisL. (2010) Synthesis and biological evaluation of dehydroabietic acid derivatives. European Journal of Medicinal Chemistry, 45, 4403–4408.
13.
(a) KobayashiJ., MurayamaT., OhizumiY., SasakiT., OhtaT., NozoeS. (1989) Theonelladins A-D, novel antineoplastic pyridine alkaloids from the Okinawan marine sponge Theonella swinhoei. Tetrahedron Letters, 30, 4833–4836;(b) Wang GYS, Kuramoto M, Uemura D, Yamada A, Yamaguchi K, Yazawa K. (1996) Three novel anti-microfouling nitroalkyl pyridine alkaloids from the Okinawan marine sponge Callyspongia sp. Tetrahedron Letters, 37, 1813–1816.
14.
PettitG.R., SinghS.B., NivenM.L., HamelE., SchmidtJ.M. (1987) Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. Journal of Natural Products, 50, 119–131.
15.
EffenbergerF., JägerJ. (1997) Synthesis of the adrenergic bronchodilators (R)-terbutaline and (R)-salbutamol from (R)-cyanohydrins. Journal of Organic Chemistry, 62, 3867–3873.
16.
(a) De la TorreM.C., GarcíaI., SierraM.A. (2002) Straightforward synthesis of the strong ambergris odorant γ-bicyclohomofarnesal and its endo-isomer from R-(+)-sclareolide. Tetrahedron Letters, 43, 6351–6353;(b) Boukouvalas J, Wang JX, Marion O, Ndzi B. (2006) Synthesis and stereochemistry of the antitumor diterpenoid (+)-zerumin B. Journal of Organic Chemistry, 71, 6670–6673.
17.
PettitG.R., SinghS.B., BoydM.R., HamelE., PettitR.K., SchmidtJ.M., HoganF. (1995) Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a). Journal of Medicinal Chemistry, 38, 1666–1672.
18.
ChengY.S., LiuW.L., ChenS.H. (1980) Pyridinium chlorochromate absorbed on alumina as a selective oxidant for primary and secondary alcohols [J]. Synthesis, 2, 223–224.
19.
YangZ. (2006) Synthesis and in vitro biological activity evaluation of the derivatives of combretastatin A-4. Letters in Drug Design & Discovery, 3, 544–546.
López-LázaroM., Calderón-MontañoJ.M., Burgos-MorónE., AustinC.A. (2011) Green tea constituents (-)-epigallocatechin-3-gallate (EGCG) and gallic acid induce topoisomerase I- and topoisomerase II-DNA complexes in cells mediated by pyrogallol-induced hydrogen peroxide. Mutagenesis, 26, 489–498.
22.
PrayongP., BarusruxS., WeerapreeyakulN., PrayongP., BarusruxS., WeerapreeyakulN. (2008) Cytotoxic activity screening of some indigenous Thai plants. Fitoterapia, 79, 598–601.
23.
Cuenca-EstrellaM., MooreC.B., BarchiesiF., BilleJ., ChryssanthouE., DenningD.W., DonnellyJ.P., DromerF., DupontB., RexJ.H., RichardsonM.D., SancakB., VerweijP.E., Rodríguez-TudelaJL., AFST Subcommittee of the European Committee on Antimicrobial Susceptibility Testing. (2003) Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 9, 467–474.
24.
National Committee for Clinical Laboratory Standards (NCCLS). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi. (2002) Approved Standard. National Committee for Clinical Laboratory Standards (NCCLS), document M38-A [ISBN 1–56238–470–8]. NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087–1898 USA.
25.
PettitR.K., PettitG.R., HamelE., HoganF., MoserB.R., WolfS., PonS., ChapuisJ.C., SchmidtJ.M. (2009) E-Combretastatin and E-resveratrol structural modifications: antimicrobial and cancer cell growth inhibitory beta-E-nitrostyrenes. Bioorganic & Medicinal Chemistry, 17, 6606–6612.
26.
Betancur-GalvisL.A., ZuluagaC., ArnóM., GonzálezM.A., ZaragozaR.J. (2002) Structure-activity relationship of cytotoxic effect on tumor cells and in vitro antiviral activity against herpes simplex virus of synthetic spongiane diterpenes. Journal of Natural Products, 65, 189–192.
27.
Agudelo-GómezL.S., Gómez RíosG.A., Durán GarcíaD.C., StashenkoE., Betancur-GalvisL. (2010) Composición química y evaluación de la actividad antiherpética in vitro de aceites esenciales de Lippia alba (Mill) N.E. Brown y sus componentes mayoritarios. Salud UIS, 42, 234–244.
28.
VlietinckA.J., Van HoofL., TottéJ., LasureA., Vanden BergheD., RwangaboP.C., MvukiyumwamiJ. (1995) Screening of hundred Rwandese medicinal plants for antimicrobial and antiviral properties. Journal of Ethnopharmacology, 46, 31–47.
29.
KratzJ.M., Andrighetti-FröhnerC.R., KollingD.J., LealP.C., Cirne-SantosC.C., YunesR.A., NunesR.J., TrybalaE., BergströmT., FrugulhettiI.C., BarardiC.R., SimőesC.M. (2008) Anti-HSV-1 and anti-HIV-1 activity of gallic acid and pentyl gallate. Memórias do Instituto Oswaldo Cruz, 103, 437–442.
30.
KratzJ.M., Andrighetti-FröhnerC.R., LealP.C., NunesR.J., YunesR.A., TrybalaE., BergströmT., BarardiC.R., SimőesC.M. (2008) Evaluation of anti-HSV-2 activity of gallic acid and pentyl gallate. Biological & Pharmaceutical Bulletin, 31, 903–907.
